Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vacuolar-type H+-ATPase catalytic subunit A (ATP6V1A) is a core component of the V1 domain of the V-ATPase complex, a multi-subunit rotary enzyme that functions as a primary proton pump in eukaryotic cells [1, 2]. This subunit is responsible for the hydrolysis of ATP, which provides the energy necessary to transport protons across biological membranes to acidify intracellular organelles such as lysosomes and endosomes [2, 19]. Such acidification is critical for essential cellular processes, including protein degradation, receptor-mediated endocytosis, and nutrient sensing through the mTORC1 pathway [8, 20]. In disease states, ATP6V1A is often dysregulated; for instance, its recruitment to the plasma membrane in cancer cells facilitates the acidification of the tumor microenvironment, promoting invasion and metastasis [14, 20]. Furthermore, mutations in the ATP6V1A gene are linked to severe conditions such as cutis laxa and developmental and epileptic encephalopathy [7]. While numerous experimental inhibitors like bafilomycin A1 and salicylihalamides target this enzyme, their clinical utility is currently limited by potential systemic toxicity given the ubiquitous role of V-ATPases in cellular homeostasis [15, 18]. Recent therapeutic efforts focus on identifying isoform-specific interactions or targeting specialized V-ATPase populations to treat osteoporosis and metastatic cancers more selectively [15, 16].
Inhibition of ATP hydrolysis within the V1 domain; Prevention of the rotational mechanism of the V-ATPase complex; Disruption of the coupling between ATP hydrolysis and proton translocation; Interference with subunit-subunit interactions within the V1 domain
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vacuolar-type H+-ATPase catalytic subunit A (ATP6V1A) (ATP6V1A).